The increase in revenue from administering vaccines and providing telehealth services has led to an expansion of pharmacy services in the U.S. Pharmacies in the U.S. offers a variety of patient-care services and implement strategies to increase medication sales. According to the 2021 National Community Pharmacy Association (NCPA) Digest, pharmacies offer their customers a wide range of services. For example, 84% of pharmacies provide flu immunizations, 80% provide non-flu immunizations, 53% offer blood pressure monitoring, and 30% offer diabetes education.
What Defines The Pharmaceutical Drugs Market?
- Metformin, metoprolol, amphetamine salt combo, acyclovir, bupropion HCL tablet, cholestyramine, ibuprofen tablet, letrozole, and verapamil are some examples of generic drugs.
- Sprays use atomization to transform a liquid or solid composition into a dynamic combination spread across a gas.
- By age group, the children & adolescent segment is estimated to witness strong growth during the forecast period.
- Other key areas include CNS disorders, immunosuppressants, vaccines, and autoimmune therapies.
The generic drugs segment is anticipated to grow at the fastest CAGR of 7.4% from 2025 to 2032, driven by patent expirations, increasing demand for cost-effective treatments, and favorable regulatory support. The oncology segment dominated the pharmaceutical market, holding 16.99% of the share in 2024. This is largely due to the increasing incidence of cancer, advancements in personalized medicine, and the development of targeted therapies. Collaborations between pharmaceutical companies and research institutions are accelerating the development of innovative oncology treatments, further driving the growth of this segment. The other prescription drugs segment held a dominant share in 2022, owing to the rise in the adoption of these drugs for pain management and diabetes treatment among the population.
Pharmaceutical Market Size, By Type (USD Billion)
They must innovate to escape commoditization, moving decisively up the value chain into more complex and defensible product categories. They must build resilient and agile supply chains, balancing the historical pursuit of low-cost production with the new geopolitical necessity of supply security. Finally, they must master the intricate complexities of a varied global regulatory and commercial landscape.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment. • By drugtype, the simple generic segment is estimated to hold the highest market shareof 60.74% in 2024.
As per our prescription drugs market forecast, the hospital pharmacies accumulated a significant market share in 2021. The high growth in this segment is credited to the stringent policies to sell drugs prescribed from healthcare providers. In addition, hospital pharmacies consists all sorts of drugs that are required to cure every disease. On the other hand, online pharmacies are anticipated to attain significant growth rate from 2022 to 2030.
Thesepharmacies serve as a crucial point of access for patients, giving them accessto generic medications for several conditions. The widespread presence ofretail pharmacies, ease of access, and affordability of generics drive highsales volume in this channel. The increasing number of product approvals and launches, such as ointments, suspensions, and gels, are gaining popularity due to their enhanced effectiveness in treating conditions like inflammation, infection, and dry eye. Unlike liquid formulations, semi-solid ophthalmic drugs offer the advantage of prolonged corneal residence time, leading to sustained drug release and improved therapeutic outcomes. Additionally, the growing focus on obtaining approvals and introducing innovative products is further propelling market growth.
LIST OF KEY COMPANIES PROFILED:
For instance, alkaloids were the first pure pharmaceuticals derived from plants; they include quinine, nicotine, cocaine, atropine, and morphine. Similarly, some drugs are made of animal origin, which includes glandular extracts containing hormones. These pharmaceutical products diagnose, treat, and prevent chronic diseases such as cancer, diabetes, and genetic disorders. This issue brief examines trends related to market size measured via sales revenues and volume of prescription drug use between the U.S. and other countries between 2017 and 2023. Specifically, we compare the U.S. to the rest of the world (excluding the U.S.) and the other OECD countries (excluding the U.S.).
The Enduring Shadow Of Quality And Safety Concerns
In response to the relentless margin pressures and commoditization inherent in the traditional generics model, the industry is undergoing a strategic metamorphosis. Instead, they are actively moving up the value chain, embracing product complexity and leveraging technological innovation to create more defensible market positions. This shift marks a new era for the industry, one defined by scientific sophistication, advanced manufacturing, and digital transformation.
Company Links
Food and Drug Administration (FDA) authorized ZURZUVAETM (zuranolone) 50 mg for people with postpartum depression (PPD), according to a statement from Biogen Inc. and Sage Therapeutics, Inc. For women with PPD, ZURZUVAE is the first and only oral, once-daily, 14-day medication that can significantly reduce depression symptoms. The U.S. over the counter (OTC) drugs market size was estimated at USD 23.84 billion in 2024 and is predicted to increase from USD 24.81 billion in 2025 to approximately USD 44.17 billion by 2034, expanding at a CAGR of 6.60% from 2025 to 2034. A Morgan Stanley AlphaWise survey, conducted in February and March 2025 among 280 people taking obesity drugs in the U.S., shows patients on weight-loss drugs experience significant changes in their food consumption and preferences. The adoption of weight-loss drugs is likely to accelerate in a pattern similar to structural changes in the technology cycle, such as the introduction of smartphones. Patients’ use will increase as they become more familiar and comfortable with the new products and as manufacturers address hurdles in production, distribution and regulatory issues.
A prime example of such a strategic move by a market player includes BioMarin, a key pharmaceutical company involved in the development of rare diseases therapies. BioMarin’s product portfolio includes several orphan drugs, such as the mucopolysaccharidoses (MPS) group of disorders, and the company also has strong orphan drug pipeline candidates in various stages of clinical trials. The market is driven by escalated life expectancy, a rising population, and the increase in chronic conditions like diabetes and hypertension, along with advancing developments in drug development like biologics and biosimilars. Govement is supporting with its policies, such as the Production-Linked Incentive (PLI) scheme, bulk drug parks, and the National R&D Policy are also propelling demand for the drugs.
Hospital And Health Systems
Around the world, an increasing geriatric patients with chronic conditions like cardiovascular diseases, diabetes, and cancer, with technological advancements in drug development, are driving the market growth. North America dominated this market in 2024, by majorly impacting factors like the adoption of technological advancements like targeted therapies and biologics with personalized medicine as well. This pharmaceutical drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Prescription Drugs Market Segmentation Analysis
The retail pharmacy segment is experiencing a significant growth rate driven by increasing consumer preference for convenient access to medications, over-the-counter (OTC) products, and health consultations. The expansion of pharmacy chains, growing online pharmacy adoption, and rising health awareness contribute to market growth. Retail pharmacies offer accessible healthcare services, including vaccinations and chronic disease management support.
The growth is attributed to the rising prevalence of chronic diseases, the high utilization of prescription drugs, and the increasing elderly population in the country. According to the health policy institute, in 2021, nearly 131 million people in the U.S. (representing 66% of adults) consumed prescription drugs. Additionally, the American Society of Health-System Pharmacists (ASHP) reported that the total drug spending in the country increased by around 8% in 2021, further indicating the high demand for prescription drugs in the country. Furthermore, funding supports generic drug manufacturers in expanding their market reach and distribution networks. It enables them to establish partnerships and collaborations with wholesalers, distributors, and healthcare providers to ensure the availability and accessibility of generic drugs to patients. Funding also facilitates market research and marketing activities to create awareness and promote the use of generic medications.
Their widespread adoption is due to their well-established manufacturing processes, predictable pharmacokinetics, and oral bioavailability. Small molecules are widely used in various therapeutic applications, and their patent expirations allow for the entry of generics, further driving market growth. They also have better membrane penetration, making them effective at targeting intracellular pathways. Growing funding plays a significant role in the development and expansion of the generic drugs market.
Along with this, healthcare systems are broadly investing in specialized drug distribution and progress in novel creation of affordable treatment approaches for patients. Saudi Arabia’s pharmaceutical market is growing, underpinned by government-led healthcare reforms and increased investment in biopharmaceutical research. Rising prevalence of chronic and infectious diseases is driving demand for effective treatment solutions. Hospital pharmacies hold a significant share of the distribution segment, while retail pharmacies are increasingly improving patient access to essential medications.
